hotspot -WSS

hotspot

author：fashion 2025-09-02 11:34:40 - browse：7518

Tortoise and hare — Medical devices have historically been seen as having faster paths to market than their pharmacological counterparts. The growing requirement for cost-effectiveness trials may be slowing them down. Jonathan Elderfield/AP

When a colleague and I started our medical device company in 2009, we were in our second year at Harvard Medical School. Some classmates joked that they would still be in residency by the time we had moved on to our next big idea. We knew better — we expected it to be a long haul. Eight years into our journey, thousands of individuals have used our product in countries where it has been approved. But we have yet to gain approval in the U.S. — a long and expensive process.

In 2016, the United States Food and Drug Administration approved 22 new drugs, down from 45 approvals in 2015. The decline in drug discovery has been attributed to a variety of factors that include ballooning research and development expenses (the cost to develop a new drug is now estimated to be more than $2.5 billion), high rates of failure (a whopping 90 percent of Phase 1 candidates never make it to launch), and the complexity of human biology, which can thwart even the most promising candidates.

Medical devices have historically been viewed as having faster and lower-cost paths to market than their pharmacological counterparts: the average cost to develop high-risk, novel medical devices is estimated to be $94 million. After all, device engineers can leverage lower-cost animal models further into development than their pharmaceutical colleagues, the human clinical trials necessary for FDA approval are often smaller in scale, and, in some cases, expenses can be defrayed by revenue generated outside the United States in markets with faster regulatory pathways.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Heart attack and stroke risk calculators need revising
Next article： The CDC's new social media misinformation war

WSS

Gut bacteria may contribute to kidney autoimmunity, study finds

Drug companies' payments and gifts affect physicians' prescribing

U.K. decision on ALS drug has neurologists, advocates up in arms

Vyjuvek, a gene therapy for skin wounds, restored vision in one boy

A protest over insulin prices is seen as a fight for life

Unique patient identifier: Experts argue the benefits, pitfalls

focus

hotspot

focus

Apple is now the first public company to be valued at $3 trillion

What’s missing from the debate over nursing home staff minimums

Peter Hotez and the public health issue of online harassment

Multiple sclerosis has subtypes with different best treatments: study

Trump demands the U.S. pay no more for drugs than other countries … again

Problems with a popular proposal to regulate AI in health care

At least 13 dead in Texas as scorching temps continue

Readout LOUD: Venture capital, Gilead, and more M&A

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Covid silver lining: Unprecedented look at human immune system

explore

Florida Supreme Court upholds state's abortion ban

Bird flu in dairy cattle: New measures to control spread to humans

AI gets buy

Vyjuvek, a gene therapy for skin wounds, restored vision in one boy

UnitedHealth, in a surprise, takes aim at Steward’s physician group

Drug companies' payments and gifts affect physicians' prescribing

explore

hotspot

hotspot

leisure time